HEADER TRANSFERASE 25-FEB-17 5N9L TITLE CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN TITLE 2 COMPLEX WITH THE ATP-COMPETITIVE DIBENZOFURAN INHIBITOR TF (4B) COMPND MOL_ID: 1; COMPND 2 MOLECULE: CASEIN KINASE II SUBUNIT ALPHA; COMPND 3 CHAIN: A; COMPND 4 SYNONYM: CK II ALPHA; COMPND 5 EC: 2.7.11.1; COMPND 6 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: CSNK2A1, CK2A1; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 562 KEYWDS PROTEIN KINASE, CK2, CASEIN KINASE 2, PROTEIN PHOSPHORYLATION, ATP- KEYWDS 2 COMPETITIVE INHITITORS, DIBENZOFURAN DERIVATIVES, TRANSFERASE, KEYWDS 3 TIGHT-BINDING INHIBITORS EXPDTA X-RAY DIFFRACTION AUTHOR A.SCHNITZLER,A.GRATZ,A.BOLLACKE,M.WEYRICH,U.KUCKLAENDER,B.WUENSCH, AUTHOR 2 C.GOETZ,K.NIEFIND,J.JOSE REVDAT 5 17-JAN-24 5N9L 1 REMARK REVDAT 4 25-APR-18 5N9L 1 JRNL REVDAT 3 18-APR-18 5N9L 1 JRNL REVDAT 2 07-MAR-18 5N9L 1 JRNL REVDAT 1 28-FEB-18 5N9L 0 JRNL AUTH A.SCHNITZLER,A.GRATZ,A.BOLLACKE,M.WEYRICH,U.KUCKLANDER, JRNL AUTH 2 B.WUNSCH,C.GOTZ,K.NIEFIND,J.JOSE JRNL TITL A PI-HALOGEN BOND OF DIBENZOFURANONES WITH THE GATEKEEPER JRNL TITL 2 PHE113 IN HUMAN PROTEIN KINASE CK2 LEADS TO POTENT TIGHT JRNL TITL 3 BINDING INHIBITORS. JRNL REF PHARMACEUTICALS V. 11 2018 JRNL REFN ESSN 1424-8247 JRNL PMID 29462988 JRNL DOI 10.3390/PH11010023 REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH I.ERMAKOVA,B.BOLDYREFF,O.G.ISSINGER,K.NIEFIND REMARK 1 TITL CRYSTAL STRUCTURE OF A C-TERMINAL DELETION MUTANT OF HUMAN REMARK 1 TITL 2 PROTEIN KINASE CK2 CATALYTIC SUBUNIT. REMARK 1 REF J. MOL. BIOL. V. 330 925 2003 REMARK 1 REFN ISSN 0022-2836 REMARK 1 PMID 12860116 REMARK 1 DOI 10.1016/S0022-2836(03)00638-7 REMARK 1 REFERENCE 2 REMARK 1 AUTH C.W.YDE,I.ERMAKOVA,O.G.ISSINGER,K.NIEFIND REMARK 1 TITL INCLINING THE PURINE BASE BINDING PLANE IN PROTEIN KINASE REMARK 1 TITL 2 CK2 BY EXCHANGING THE FLANKING SIDE-CHAINS GENERATES A REMARK 1 TITL 3 PREFERENCE FOR ATP AS A COSUBSTRATE. REMARK 1 REF J. MOL. BIOL. V. 347 399 2005 REMARK 1 REFN ISSN 0022-2836 REMARK 1 PMID 15740749 REMARK 1 DOI 10.1016/J.JMB.2005.01.003 REMARK 1 REFERENCE 3 REMARK 1 AUTH K.NIEFIND,N.BISCHOFF,A.G.GOLUB,V.G.BDZHOLA,A.O.BALANDA, REMARK 1 AUTH 2 A.O.PRYKHOD'KO,S.M.YARMOLUK REMARK 1 TITL STRUCTURAL HYPERVARIABILITY OF THE TWO HUMAN PROTEIN KINASE REMARK 1 TITL 2 CK2 CATALYTIC SUBUNIT PARALOGS REVEALED BY COMPLEX REMARK 1 TITL 3 STRUCTURES WITH A FLAVONOL- AND A REMARK 1 TITL 4 THIENO[2,3-D]PYRIMIDINE-BASED INHIBITOR. REMARK 1 REF PHARMACEUTICALS (BASEL) V. 10 2017 REMARK 1 REFN ESSN 1424-8247 REMARK 1 PMID 28085026 REMARK 1 DOI 10.3390/PH10010009 REMARK 1 REFERENCE 4 REMARK 1 AUTH C.GOETZ,A.GRATZ,U.KUCKLAENDER,J.JOSE REMARK 1 TITL TF--A NOVEL CELL-PERMEABLE AND SELECTIVE INHIBITOR OF HUMAN REMARK 1 TITL 2 PROTEIN KINASE CK2 INDUCES APOPTOSIS IN THE PROSTATE CANCER REMARK 1 TITL 3 CELL LINE LNCAP. REMARK 1 REF BIOCHIM. BIOPHYS. ACTA V.1820 970 2012 REMARK 1 REFN ISSN 0006-3002 REMARK 1 PMID 22387500 REMARK 1 DOI 10.1016/J.BBAGEN.2012.02.009 REMARK 2 REMARK 2 RESOLUTION. 1.79 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : PHENIX (1.11.1_2575: ???) REMARK 3 AUTHORS : PAUL ADAMS,PAVEL AFONINE,VINCENT CHEN,IAN REMARK 3 : DAVIS,KRESHNA GOPAL,RALF GROSSE-KUNSTLEVE, REMARK 3 : LI-WEI HUNG,ROBERT IMMORMINO,TOM IOERGER, REMARK 3 : AIRLIE MCCOY,ERIK MCKEE,NIGEL MORIARTY, REMARK 3 : REETAL PAI,RANDY READ,JANE RICHARDSON, REMARK 3 : DAVID RICHARDSON,TOD ROMO,JIM SACCHETTINI, REMARK 3 : NICHOLAS SAUTER,JACOB SMITH,LAURENT REMARK 3 : STORONI,TOM TERWILLIGER,PETER ZWART REMARK 3 REMARK 3 REFINEMENT TARGET : NULL REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.79 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 36.14 REMARK 3 MIN(FOBS/SIGMA_FOBS) : 1.390 REMARK 3 COMPLETENESS FOR RANGE (%) : 95.3 REMARK 3 NUMBER OF REFLECTIONS : 27726 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 R VALUE (WORKING + TEST SET) : 0.165 REMARK 3 R VALUE (WORKING SET) : 0.164 REMARK 3 FREE R VALUE : 0.199 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.010 REMARK 3 FREE R VALUE TEST SET COUNT : 1389 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT (IN BINS). REMARK 3 BIN RESOLUTION RANGE COMPL. NWORK NFREE RWORK RFREE REMARK 3 1 36.1427 - 3.8552 0.98 2770 170 0.1481 0.1667 REMARK 3 2 3.8552 - 3.0605 0.98 2738 137 0.1444 0.1838 REMARK 3 3 3.0605 - 2.6738 0.98 2741 130 0.1707 0.2119 REMARK 3 4 2.6738 - 2.4294 0.97 2658 145 0.1715 0.2189 REMARK 3 5 2.4294 - 2.2553 0.97 2681 146 0.1733 0.2151 REMARK 3 6 2.2553 - 2.1223 0.96 2653 117 0.1737 0.2357 REMARK 3 7 2.1223 - 2.0161 0.96 2620 159 0.1751 0.2335 REMARK 3 8 2.0161 - 1.9283 0.97 2660 131 0.1936 0.1978 REMARK 3 9 1.9283 - 1.8541 0.96 2642 140 0.2049 0.2682 REMARK 3 10 1.8541 - 1.7901 0.79 2174 114 0.2392 0.2826 REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : NULL REMARK 3 SOLVENT RADIUS : 1.11 REMARK 3 SHRINKAGE RADIUS : 0.90 REMARK 3 K_SOL : NULL REMARK 3 B_SOL : NULL REMARK 3 REMARK 3 ERROR ESTIMATES. REMARK 3 COORDINATE ERROR (MAXIMUM-LIKELIHOOD BASED) : 0.180 REMARK 3 PHASE ERROR (DEGREES, MAXIMUM-LIKELIHOOD BASED) : 21.340 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : NULL REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : NULL REMARK 3 B22 (A**2) : NULL REMARK 3 B33 (A**2) : NULL REMARK 3 B12 (A**2) : NULL REMARK 3 B13 (A**2) : NULL REMARK 3 B23 (A**2) : NULL REMARK 3 REMARK 3 TWINNING INFORMATION. REMARK 3 FRACTION: NULL REMARK 3 OPERATOR: NULL REMARK 3 REMARK 3 DEVIATIONS FROM IDEAL VALUES. REMARK 3 RMSD COUNT REMARK 3 BOND : 0.003 2954 REMARK 3 ANGLE : 0.664 3998 REMARK 3 CHIRALITY : 0.045 406 REMARK 3 PLANARITY : 0.005 515 REMARK 3 DIHEDRAL : 12.671 1754 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : 3 REMARK 3 TLS GROUP : 1 REMARK 3 SELECTION: CHAIN 'A' AND (RESID 2 THROUGH 88 ) REMARK 3 ORIGIN FOR THE GROUP (A): -18.3945 3.0423 46.0867 REMARK 3 T TENSOR REMARK 3 T11: 0.2301 T22: 0.3382 REMARK 3 T33: 0.3428 T12: -0.0494 REMARK 3 T13: 0.0074 T23: 0.0445 REMARK 3 L TENSOR REMARK 3 L11: 3.4446 L22: 2.0929 REMARK 3 L33: 0.5566 L12: -1.8595 REMARK 3 L13: 0.2616 L23: -0.3389 REMARK 3 S TENSOR REMARK 3 S11: -0.0008 S12: -0.1983 S13: -0.4108 REMARK 3 S21: -0.0139 S22: 0.1052 S23: 0.4420 REMARK 3 S31: 0.1112 S32: -0.2015 S33: -0.1008 REMARK 3 TLS GROUP : 2 REMARK 3 SELECTION: CHAIN 'A' AND (RESID 89 THROUGH 249 ) REMARK 3 ORIGIN FOR THE GROUP (A): -5.0760 10.6099 43.8001 REMARK 3 T TENSOR REMARK 3 T11: 0.1547 T22: 0.1480 REMARK 3 T33: 0.1682 T12: 0.0148 REMARK 3 T13: -0.0105 T23: 0.0175 REMARK 3 L TENSOR REMARK 3 L11: 2.1458 L22: 0.8376 REMARK 3 L33: 1.2202 L12: -0.1187 REMARK 3 L13: -0.0609 L23: -0.0047 REMARK 3 S TENSOR REMARK 3 S11: 0.0142 S12: -0.1131 S13: 0.0766 REMARK 3 S21: -0.0594 S22: 0.0039 S23: 0.2159 REMARK 3 S31: -0.0980 S32: -0.1454 S33: -0.0195 REMARK 3 TLS GROUP : 3 REMARK 3 SELECTION: CHAIN 'A' AND (RESID 250 THROUGH 330 ) REMARK 3 ORIGIN FOR THE GROUP (A): 11.5942 9.7354 41.2006 REMARK 3 T TENSOR REMARK 3 T11: 0.1573 T22: 0.2008 REMARK 3 T33: 0.2061 T12: 0.0072 REMARK 3 T13: -0.0083 T23: 0.0108 REMARK 3 L TENSOR REMARK 3 L11: 1.2146 L22: 2.2117 REMARK 3 L33: 2.4436 L12: 0.1974 REMARK 3 L13: 0.1249 L23: 1.0343 REMARK 3 S TENSOR REMARK 3 S11: -0.0056 S12: 0.0315 S13: -0.0159 REMARK 3 S21: -0.1244 S22: 0.0724 S23: -0.0916 REMARK 3 S31: -0.0349 S32: 0.2024 S33: -0.0685 REMARK 3 REMARK 3 NCS DETAILS REMARK 3 NUMBER OF NCS GROUPS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 5N9L COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 25-FEB-17. REMARK 100 THE DEPOSITION ID IS D_1200003734. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 12-OCT-12 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 5.6 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : SLS REMARK 200 BEAMLINE : X06DA REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.99987 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : PIXEL REMARK 200 DETECTOR MANUFACTURER : DECTRIS PILATUS 2M REMARK 200 INTENSITY-INTEGRATION SOFTWARE : XDS REMARK 200 DATA SCALING SOFTWARE : AIMLESS REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 27738 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.790 REMARK 200 RESOLUTION RANGE LOW (A) : 36.140 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 95.1 REMARK 200 DATA REDUNDANCY : 3.500 REMARK 200 R MERGE (I) : 0.05600 REMARK 200 R SYM (I) : 0.05600 REMARK 200 FOR THE DATA SET : 11.3000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.79 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.83 REMARK 200 COMPLETENESS FOR SHELL (%) : 65.9 REMARK 200 DATA REDUNDANCY IN SHELL : 2.90 REMARK 200 R MERGE FOR SHELL (I) : 0.54500 REMARK 200 R SYM FOR SHELL (I) : 0.54500 REMARK 200 FOR SHELL : 1.500 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: PHASER REMARK 200 STARTING MODEL: 2PVR REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 36.38 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 1.93 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: PRIOR TO THE CRYSTALLIZATION TF WAS REMARK 280 SOLUBILIZED IN 100 % DMSO IN A CONCENTRATION OF 10 MM. TF WAS REMARK 280 MIXED WITH HUMAN CK2ALPHA (CONSTRUCT 1-335; 8-10 MG/ML IN 500 MM REMARK 280 SODIUM CHLORIDE, 25 MM TRIS/HCL PH 8.5) IN A RATIO OF 1:5. AFTER REMARK 280 A SHORT TIME OF INCUBATION THIS MIXTURE WAS MIXED WITH RESERVOIR REMARK 280 SOLUTION [32 % (W/V) PEG4000, 0.2 M AMMONIUM ACETATE, 0.1 M REMARK 280 CITRATE PH 5.6] IN A RATIO OF 5:2. 3.5 MICROLITER OF THE REMARK 280 RESULTING MIXTURE WAS THEN EQUILIBRATED AGAINST THE RESERVOIR REMARK 280 SOLUTION. THE CRYSTAL GROWTH WAS INDUCED BY SEEDING WITH 150 REMARK 280 NANOLITER SEED SUSPENSION AFTER AN EQUILIBRATION TIME OF TWO REMARK 280 DAYS., VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 293K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 1 21 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 22.85300 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 1390 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 15440 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: 1.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 MET A 1 REMARK 465 GLN A 331 REMARK 465 ALA A 332 REMARK 465 ARG A 333 REMARK 465 MET A 334 REMARK 465 GLY A 335 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS IN SAME ASYMMETRIC UNIT REMARK 500 REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT. REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI DISTANCE REMARK 500 O HOH A 627 O HOH A 686 2.16 REMARK 500 O HOH A 654 O HOH A 712 2.19 REMARK 500 O HOH A 648 O HOH A 680 2.19 REMARK 500 O HOH A 676 O HOH A 713 2.19 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ASN A 61 10.40 -145.37 REMARK 500 VAL A 73 -63.20 -141.82 REMARK 500 LYS A 74 128.60 -175.63 REMARK 500 ASP A 156 42.59 -147.84 REMARK 500 ASP A 175 79.63 43.77 REMARK 500 ALA A 193 159.69 64.07 REMARK 500 MET A 208 58.65 -91.64 REMARK 500 HIS A 234 73.43 -106.62 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue 8QH A 401 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue ACT A 402 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue ACT A 403 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC4 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue GOL A 404 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC5 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue GOL A 405 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC6 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue GOL A 406 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC7 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue GOL A 407 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 5N9N RELATED DB: PDB REMARK 900 RELATED ID: 5N9K RELATED DB: PDB DBREF 5N9L A 1 335 UNP P68400 CSK21_HUMAN 1 335 SEQRES 1 A 335 MET SER GLY PRO VAL PRO SER ARG ALA ARG VAL TYR THR SEQRES 2 A 335 ASP VAL ASN THR HIS ARG PRO ARG GLU TYR TRP ASP TYR SEQRES 3 A 335 GLU SER HIS VAL VAL GLU TRP GLY ASN GLN ASP ASP TYR SEQRES 4 A 335 GLN LEU VAL ARG LYS LEU GLY ARG GLY LYS TYR SER GLU SEQRES 5 A 335 VAL PHE GLU ALA ILE ASN ILE THR ASN ASN GLU LYS VAL SEQRES 6 A 335 VAL VAL LYS ILE LEU LYS PRO VAL LYS LYS LYS LYS ILE SEQRES 7 A 335 LYS ARG GLU ILE LYS ILE LEU GLU ASN LEU ARG GLY GLY SEQRES 8 A 335 PRO ASN ILE ILE THR LEU ALA ASP ILE VAL LYS ASP PRO SEQRES 9 A 335 VAL SER ARG THR PRO ALA LEU VAL PHE GLU HIS VAL ASN SEQRES 10 A 335 ASN THR ASP PHE LYS GLN LEU TYR GLN THR LEU THR ASP SEQRES 11 A 335 TYR ASP ILE ARG PHE TYR MET TYR GLU ILE LEU LYS ALA SEQRES 12 A 335 LEU ASP TYR CYS HIS SER MET GLY ILE MET HIS ARG ASP SEQRES 13 A 335 VAL LYS PRO HIS ASN VAL MET ILE ASP HIS GLU HIS ARG SEQRES 14 A 335 LYS LEU ARG LEU ILE ASP TRP GLY LEU ALA GLU PHE TYR SEQRES 15 A 335 HIS PRO GLY GLN GLU TYR ASN VAL ARG VAL ALA SER ARG SEQRES 16 A 335 TYR PHE LYS GLY PRO GLU LEU LEU VAL ASP TYR GLN MET SEQRES 17 A 335 TYR ASP TYR SER LEU ASP MET TRP SER LEU GLY CYS MET SEQRES 18 A 335 LEU ALA SER MET ILE PHE ARG LYS GLU PRO PHE PHE HIS SEQRES 19 A 335 GLY HIS ASP ASN TYR ASP GLN LEU VAL ARG ILE ALA LYS SEQRES 20 A 335 VAL LEU GLY THR GLU ASP LEU TYR ASP TYR ILE ASP LYS SEQRES 21 A 335 TYR ASN ILE GLU LEU ASP PRO ARG PHE ASN ASP ILE LEU SEQRES 22 A 335 GLY ARG HIS SER ARG LYS ARG TRP GLU ARG PHE VAL HIS SEQRES 23 A 335 SER GLU ASN GLN HIS LEU VAL SER PRO GLU ALA LEU ASP SEQRES 24 A 335 PHE LEU ASP LYS LEU LEU ARG TYR ASP HIS GLN SER ARG SEQRES 25 A 335 LEU THR ALA ARG GLU ALA MET GLU HIS PRO TYR PHE TYR SEQRES 26 A 335 THR VAL VAL LYS ASP GLN ALA ARG MET GLY HET 8QH A 401 26 HET ACT A 402 4 HET ACT A 403 4 HET GOL A 404 6 HET GOL A 405 6 HET GOL A 406 6 HET GOL A 407 6 HETNAM 8QH (4~{Z})-6,7-BIS(CHLORANYL)-4-[[(4-METHYLPHENYL) HETNAM 2 8QH AMINO]METHYLIDENE]-8-OXIDANYL-1,2-DIHYDRODIBENZOFURAN- HETNAM 3 8QH 3-ONE HETNAM ACT ACETATE ION HETNAM GOL GLYCEROL HETSYN GOL GLYCERIN; PROPANE-1,2,3-TRIOL FORMUL 2 8QH C20 H15 CL2 N O3 FORMUL 3 ACT 2(C2 H3 O2 1-) FORMUL 5 GOL 4(C3 H8 O3) FORMUL 9 HOH *218(H2 O) HELIX 1 AA1 PRO A 20 ASP A 25 1 6 HELIX 2 AA2 TYR A 26 HIS A 29 5 4 HELIX 3 AA3 ASN A 35 ASP A 37 5 3 HELIX 4 AA4 LYS A 74 ARG A 89 1 16 HELIX 5 AA5 ASP A 120 GLN A 126 1 7 HELIX 6 AA6 THR A 129 MET A 150 1 22 HELIX 7 AA7 LYS A 158 HIS A 160 5 3 HELIX 8 AA8 SER A 194 LYS A 198 5 5 HELIX 9 AA9 GLY A 199 VAL A 204 1 6 HELIX 10 AB1 TYR A 211 ARG A 228 1 18 HELIX 11 AB2 ASP A 237 GLY A 250 1 14 HELIX 12 AB3 GLY A 250 TYR A 261 1 12 HELIX 13 AB4 ASP A 266 ILE A 272 5 7 HELIX 14 AB5 ARG A 280 VAL A 285 5 6 HELIX 15 AB6 ASN A 289 VAL A 293 5 5 HELIX 16 AB7 SER A 294 LEU A 305 1 12 HELIX 17 AB8 ASP A 308 ARG A 312 5 5 HELIX 18 AB9 THR A 314 GLU A 320 1 7 HELIX 19 AC1 HIS A 321 TYR A 325 5 5 SHEET 1 AA1 5 TYR A 39 ARG A 47 0 SHEET 2 AA1 5 SER A 51 ASN A 58 -1 O GLU A 55 N VAL A 42 SHEET 3 AA1 5 LYS A 64 LEU A 70 -1 O ILE A 69 N GLU A 52 SHEET 4 AA1 5 PRO A 109 GLU A 114 -1 O PHE A 113 N VAL A 66 SHEET 5 AA1 5 LEU A 97 LYS A 102 -1 N VAL A 101 O ALA A 110 SHEET 1 AA2 2 ILE A 152 MET A 153 0 SHEET 2 AA2 2 GLU A 180 PHE A 181 -1 O GLU A 180 N MET A 153 SHEET 1 AA3 2 VAL A 162 ASP A 165 0 SHEET 2 AA3 2 LYS A 170 LEU A 173 -1 O LYS A 170 N ASP A 165 CISPEP 1 GLU A 230 PRO A 231 0 -1.87 SITE 1 AC1 13 ARG A 47 GLY A 48 SER A 51 VAL A 53 SITE 2 AC1 13 VAL A 66 LYS A 68 PHE A 113 VAL A 116 SITE 3 AC1 13 MET A 163 ILE A 174 ASP A 175 HOH A 592 SITE 4 AC1 13 HOH A 669 SITE 1 AC2 3 ARG A 80 ARG A 155 LEU A 178 SITE 1 AC3 4 ASP A 156 LYS A 158 ALA A 193 SER A 194 SITE 1 AC4 7 GLY A 90 GLY A 91 PRO A 92 ASN A 93 SITE 2 AC4 7 ILE A 94 ARG A 172 HOH A 529 SITE 1 AC5 4 GLU A 32 GLU A 86 ARG A 89 ILE A 100 SITE 1 AC6 4 GLN A 310 SER A 311 ARG A 312 GLU A 317 SITE 1 AC7 8 GLN A 36 TYR A 39 ASP A 103 PRO A 104 SITE 2 AC7 8 ALA A 110 ARG A 280 HOH A 638 HOH A 651 CRYST1 57.437 45.706 63.187 90.00 110.94 90.00 P 1 21 1 2 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.017410 0.000000 0.006663 0.00000 SCALE2 0.000000 0.021879 0.000000 0.00000 SCALE3 0.000000 0.000000 0.016945 0.00000